Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEX-AR
NCT07748624Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of arumakimig in VEXAS syndrome (VEXAS), sponsored by Novartis. Started Oct 2026; status: recruiting.
02
Drugs
arumakimig
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on NCT07748624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748624.